| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8965608 | Vaccine | 2018 | 9 Pages |
Abstract
QIV was non-inferior in immunogenicity to TIV for matched strains and superior to the alternate-lineage B-strains in TIV. Safety and tolerability profiles of QIV and TIV were comparable.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Serge van de Witte, Jos Nauta, Emanuele Montomoli, Jos Weckx,